Pharmacotherapy for gestational diabetes
The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. AREAS COVERED: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. EXPERT OPINION: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been established for use, but favorable experience has now also accumulated with the newer insulins (aspart, lispro, detemir). Alternatively, metformin and glyburide have been used in GDM, but they have never gained wide acceptance. Nutritional supplements based on micronutrients and bioactives (probiotics and myoinositol) have shown promising results as well. Further experience with incretin agents (DPP-4 inhibitors and GLP-1 receptor agonists) is awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428 · cited 1×
“N-3 long-chain polyunsaturated fatty acids (LCPUFA) may have beneficial effects on insulin action and improve glucose tolerance [95].”
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 1×
“The IADPSG recommends testing women early in pregnancy for overt diabetes [12] between 24th and 28th weeks of gestation [19].”
MethodEsposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 6×
“Carotid intima-media thickness (CIMT) is a non-invasive marker of subclinical atherosclerosis [33] and is a surrogate marker of CVD in metabolic patients [33].”
BackgroundInfluentialMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Vitamin D supplementation for women during pregnancy
De-Regil, L. M., Palacios, C., Lombardo, L. K., & Peña-Rosas, J. P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008873.pub3 · Cited by 744
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Gestational Diabetes Mellitus: Risks and Management during and after Pregnancy
Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.96 · Cited by 718
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Research works printed but not linked: 7
- O’Sullivan JB, 1966, Obstet Gynecol, 27, 683
- Jenum AK, 2013, Food Nutr Res, 57
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2013, Can J Diabetes, 37, S168
- Berneis K, 2004, Swiss Med Wkly, 134, 720
- Zárate A, 2000, Ginecol Obstet Mex, 68, 42
- de-Regil LM, 2016, Cochrane Database Syst Rev, 1, CD008873
- Food and Drug Administration, HHS [Corporate authors], 2014, Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling
Cited by
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Metadata
- Authors
- Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N.
- Affiliations
- University of Palermo (IT)
- Democritus University of Thrace (GR)
- Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2018-08-23
- Volume
- 19
- Issue
- 13
- Pages
- 1407-1414
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2888321467
- Cited by
- 19
- References
- 110
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 2
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Funders
- not funded or sponsored
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- gestational diabetes mellitus, insulin therapy, NPH insulin, soluble insulin, insulin aspart, insulin lispro, insulin detemir, metformin, glibenclamide, lifestyle management, micronutrient supplementation, probiotics, myo-inositol, DPP-4 inhibitors, GLP-1 receptor agonists, insulin resistance, macrosomia
- MeSH terms
- Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, Pregnancy Complications, Diabetes, Gestational, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy for gestational diabetes. https://app.cochat.ai/papers/10.1080/14656566.2018.1509955
- The paper
- Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018). Pharmacotherapy for gestational diabetes. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2018.1509955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.